Eliquis Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Eliquis Availability in 2026

Eliquis (Apixaban) remains the most widely prescribed oral anticoagulant in the United States, with tens of millions of prescriptions filled annually. In 2026, several converging factors — Medicare price negotiations, the continued absence of generic competition, and shifting insurance formularies — are affecting how patients access this medication. Here's what prescribers need to know.

Timeline: Key Events Affecting Eliquis Access

• 2012: FDA approves Eliquis for stroke prevention in nonvalvular atrial fibrillation
• 2014: Expanded approval for DVT/PE treatment and prophylaxis
• 2023-2024: FDA approves generic Apixaban applications from Indoco, Hetero Labs, Sun Pharma, and Accord
• August 2024: CMS announces negotiated Medicare price of $231/month (down from $521 list price)
• January 1, 2026: Negotiated Medicare price takes effect; Part D out-of-pocket cap set at $2,000/year
• April 2028 (projected): Generic Apixaban expected to launch commercially

Prescribing Implications

Supply Chain Disruption Without Formal Shortage

Eliquis is not listed on the FDA or ASHP drug shortage databases. Manufacturing output remains stable. However, providers should be aware that patients are reporting difficulty filling prescriptions at retail pharmacies. This is a distribution-level issue driven by:

• Sustained high demand for brand-name Eliquis as the sole available product
• Pharmacy inventory adjustments in response to new Medicare reimbursement rates
• Wholesaler redistribution patterns shifting with new pricing economics
• Annual formulary changes triggering prescription volume spikes in Q1

Patient Impact

For patients on chronic Eliquis therapy, even a 2-3 day gap can be clinically significant. The boxed warning regarding premature discontinuation — specifically the increased risk of thrombotic events including stroke — makes continuity of therapy essential. Providers should proactively address potential access barriers during office visits.

Current Availability Picture

Both the 2.5 mg and 5 mg tablet strengths remain available through standard distribution channels. The issue is pharmacy-level stock-outs rather than systemic unavailability. Key points for providers:

• Chain pharmacies are more likely to experience stock-outs due to higher prescription volume
• Independent and specialty pharmacies often maintain more consistent inventory
• Mail-order pharmacies generally have reliable supply for 90-day fills
• Hospital pharmacies are well-stocked through direct wholesaler relationships

Cost and Access Landscape in 2026

Medicare Patients

The Inflation Reduction Act's negotiated price represents a significant change:

• Negotiated price: ~$231/month (vs. ~$521 list price) — a 56% reduction
• Out-of-pocket cap: $2,000/year across all Part D drugs (down from ~$3,300 in 2024)
• Impact: Improved affordability should reduce cost-related non-adherence among Medicare beneficiaries

Commercially Insured Patients

Coverage varies by plan, but Eliquis is covered by most commercial formularies, often at Tier 3 (preferred brand). Key resources:

• Eliquis Co-Pay Card: Eligible patients may pay as little as $0 (valid through December 31, 2026)
• Prior authorization: Some plans require PA, particularly after formulary changes

Uninsured / Underinsured Patients

• Direct-to-patient program: BMS/Pfizer's Eliquis 360 offers >40% off list price for cash-paying patients (855-354-7847)
• Patient Assistance Foundation: Free Eliquis for qualifying patients (1-800-736-0003)
• Discount cards: SingleCare, GoodRx, and other programs can reduce retail cost to approximately $155-$350/month

For patient-facing savings information, consider directing patients to savings resources for Eliquis.

Tools and Resources for Providers

Medfinder for Providers

Medfinder offers a provider-facing tool to help clinical teams locate pharmacy availability for patients. When a patient reports difficulty filling their prescription, your team can use Medfinder to quickly identify pharmacies with Eliquis in stock in the patient's area.

Therapeutic Alternatives

When Eliquis is unavailable or cost-prohibitive, evidence-based alternatives include:

• Xarelto (Rivaroxaban): Factor Xa inhibitor, once-daily dosing. Similar efficacy profile. Also brand-only.
• Pradaxa (Dabigatran): Direct thrombin inhibitor, twice daily. Advantage: specific reversal agent (Praxbind/idarucizumab).
• Savaysa (Edoxaban): Factor Xa inhibitor, once daily. Note: reduced efficacy in patients with CrCl >95 mL/min for AFib indication.
• Warfarin: Vitamin K antagonist. Very low cost ($4-$10/month). Requires INR monitoring. Consider for patients where cost is the primary barrier and monitoring is feasible.

Switching between anticoagulants requires careful attention to washout periods and bridging protocols. Refer to current ACC/AHA guidelines for transition recommendations.

Prescribing Best Practices During Access Challenges

1. Prescribe with pharmacy flexibility: When possible, do not restrict prescriptions to a single pharmacy. Allow patients to fill at whichever location has stock.
2. Discuss access proactively: Ask patients at each visit whether they're having trouble filling their Eliquis prescription.
3. Consider 90-day prescriptions: Longer fills reduce the frequency of potential stock-out encounters and are often available through mail-order.
4. Document alternatives: If a patient may need to switch, note acceptable alternatives in the chart so transitions can happen quickly if needed.
5. Provide bridge plans: For patients who may face gaps, discuss what to do if they can't get their refill on time (e.g., when to call the office, emergency options).

Looking Ahead

The Eliquis access picture should improve over the next two years:

• 2026: Supply chain adjusts to new Medicare pricing; pharmacy inventory patterns stabilize
• 2027: Additional pricing and formulary data available to optimize procurement
• April 2028: Generic Apixaban expected to launch, significantly expanding supply and reducing cost

Until generic availability, providers play a critical role in ensuring therapy continuity. Proactive conversations about access, cost, and contingency plans will help patients stay on therapy.

Final Thoughts

Eliquis remains a cornerstone of anticoagulation therapy, but the 2026 landscape requires providers to be more attuned to access and affordability challenges than in previous years. Use tools like Medfinder for Providers to help patients locate their medication, stay informed about the evolving pricing landscape, and maintain open communication with your patients about potential barriers to adherence.

For patient-facing resources, consider sharing these guides: How to Find Eliquis in Stock and Eliquis Shortage Update for Patients.